Invention Grant
- Patent Title: Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
- Patent Title (中): 确定癌症对表皮生长因子受体靶向治疗的反应性的方法
-
Application No.: US13896772Application Date: 2013-05-17
-
Publication No.: US09035036B2Publication Date: 2015-05-19
- Inventor: Daphne Winifred Bell , Daniel A. Haber , Pasi Antero Janne , Bruce E. Johnson , Thomas J. Lynch , Matthew Meyerson , Juan Guillermo Paez , William R. Sellers , Jeffrey E. Settleman , Raffaella Sordella
- Applicant: The General Hospital Corporation , Dana-Farber Cancer Institute, Inc.
- Applicant Address: US MA Boston US MA Boston
- Assignee: The General Hospital,Dana-Farber Cancer Institute, Inc.
- Current Assignee: The General Hospital,Dana-Farber Cancer Institute, Inc.
- Current Assignee Address: US MA Boston US MA Boston
- Agent Shayne Y. Huff; David S. Resnick
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C12Q1/48 ; C12Q1/68 ; G01N33/574 ; G01N33/74
Abstract:
Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Public/Granted literature
- US20130316935A1 METHOD TO DETERMINE RESPONSIVENESS OF CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING TREATMENTS Public/Granted day:2013-11-28
Information query
